ROCKVILLE, Md., Oct. 28, 2009 (GLOBE NEWSWIRE) -- Nabi Biopharmaceuticals (Nasdaq:NABI) announced that it is participating in an investigator initiated Phase IIb study to evaluate the safety and efficacy of NicVAX(R) (Nicotine Conjugate Vaccine) when co-administered with varenicline as an aid to smoking cessation and relapse prevention. This study will be conducted by The Research School CAPHRI of the Maastricht University Medical Center in Maastricht, The Netherlands and will be funded primarily by The Netherlands Organization for Health Research and Development and Maastricht University with Nabi providing some additional support.
